Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Radiotherapy for Oligometastatic Lung Adenocarcinoma
NCT03905317Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in lung adenocarcinoma, sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03905317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905317.